Pioneering a disruptive
therapeutic modality

Transformative medicines for
Deubiquitination Therapeutics

April 25, 2023

Stablix and Vertex Establish Strategic Collaboration to Discover and Develop Targeted Protein Stabilization Therapeutics

All News

Our Approach

Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. We are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drugging targets by establishing a powerful small-molecule modality for a wide variety of devastating diseases.

The big idea

Aberrant ubiquitination is a driver of disease.

This could be due to a number of reasons:

Excessive protein degradation
Localization of proteins in the “wrong” compartment
Pathway activation through primary ubiquitination step

Targeted deubiquitination can be beneficial to address these issues and restore normal function.

The challenge

123-456-7890

Drugging a universal post translational
signal – ubiquitin – in a target-specific manner

The solution

Find us on Facebook

Establishing an adaptable platform
for restoring protein stability and normal function

our approach

Reduced protein expression and aberrant activation of cell growth and immune signaling cascades are common underlying drivers of disease. Genetic mutations can reduce the stability of proteins with essential function; tumor cells often eliminate key regulatory factors to grow unchecked; pathogens co-opt the host ubiquitin-proteasome system (UPS) to modulate immune response. Ubiquitin is the master regulator of protein lifecycle and activity, involved in both protein degradation and protein activation and signaling. Deubiquitinases (DUBs) are nature’s ubiquitin editors, involved in broad biological activities, and have emerged as a highly sought-after therapeutic target.

Our Approach

At Stablix, we are establishing a new paradigm for tackling diverse diseases by harnessing the power of the body’s own cellular machinery. We generate heterobifunctional small molecules that selectively recruit active deubiquitinases (DUBs) to target proteins to precisely remove ubiquitin. Targeting proteins subject to aberrant ubiquitination restores deficient proteins to therapeutic levels pr alternatively restores normal function. We are leveraging targeted deubiquitination to develop programs to cancer, rare diseases and immunological disorders.

our platform

our team

Who We Are

Stablix, co-located at sites in New York City and Boston, is a preclinical stage biotechnology company, pioneering small molecule medicines for targeted deubiquitination therapeutics. We are an experienced, multi-disciplinary team with a combined power of industry knowledge and creative talent.